Please login to the form below

rivaroxaban

This page shows the latest rivaroxaban news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer

Latest news

CHMP backs Lynparza in breast cancer, Dupixent in asthma

It was rejected by the CHMP a year ago. Ondexxya is intended for use in patients taking Pfizer/Bristol-Myers Squibb's Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) as
Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.
Joerg Moeller to head Bayer R&D after operational shake-up

It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase
J&J files would-be prostate cancer blockbuster in US

That view was echoed by Jefferies Jeffrey Holford, who says J&J’s so-called TIRADE products - Tremfya (guselkumab) for psoriasis, cancer drug Imbruvica (ibrutinib), anticoagulant rivaroxaban (Xarelto), apalutamide, Darzalex (daratumumab)
Xarelto no better than aspirin in secondary stroke study

While bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm, according to the two companies. ... We are committed to continuing the extensive investigation of rivaroxaban for

More from news
Approximately 9 fully matching, plus 95 partially matching documents found.

Latest Intelligence

Modern anticoagulants threaten status quo

Rivaroxaban. Rivaroxaban (Xarelto; Bayer and Johnson &Johnson) is an oral, once-daily, selective factor Xa inhibitor that is approved in the EU and US for the prevention of stroke and systemic ... In addition, rivaroxaban significantly reduced

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW

There was also a greater number of generic products. Anticoagulant therapies such as apixaban, rivaroxaban and edoxaban topped the spending charts, while respiratory products such as inhalable treatments for asthma and
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

This was followed by anti-coagulant medication (£740 million), where there were notable increases in spending on drugs such as apixaban (up 16 per cent), rivaroxaban (up 5.1 per cent)